Assessing the impact of treatment of asymptomatic malaria infections on inflammation and cognition in schoolchildren

Ended Project Grant Awarded Last action

Award ID
R21AI180840
Recipient
Awarding agency
Obligated
$1,087,249

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date
Place of performance
Indiana, USA

Award details come from USAspending.gov.

Description

Abstract
Malaria causes high morbidity and mortality globally with 247 million cases and 619,000 deaths in 2021, >90% of which occurred in children living in sub-saharan africa. Children who survive repeated episodes of symptomatic malaria caused by the plasmodium falciparum parasite still do not thrive. Repeated malaria exposures eventually confer clinical immunity whereby these children can be "asymptomatically" infected with the parasite. These asymptomatic p. Falciparum infections, while not clinically apparent, have significant individual and public health consequences, including chronic anemia, increased susceptibility to bacterial sepsis, and maintenance of onward malaria transmission by serving as parasite reservoirs. Prior studies suggest that asymptomatic infections can also adversely impact cognitive performance in school-aged children. In asymptomatic malaria infections, parasite density directly correlates with markers of systemic inflammation. Systemic inflammation, as measured by circulating inflammatory cytokines, has been proposed to mechanistically alter brain development. Despite the potential mechanistic links, IT remains unknown whether systemic inflammation mediates the relationship between asymptomatic p. Falciparum infections and cognitive performance. Based on this prior evidence and our preliminary data, we hypothesize that 1) asymptomatic p. Falciparum parasitemia reduces cognitive performance; 2) treatment of microscopy-detectable asymptomatic parasitemia can reverse such reductions in cognition; and 3) subclinical inflammation, as measured by pro- inflammatory plasma cytokines, partially mediates the effect asymptomatic p. Falciparum parasitemia on cognitive performance in young schoolchildren. To test these hypotheses, we will conduct a 10-week interventional trial in asymptomatic children aged 7-9 years (n=300, 50% female) residing in western kenya whereby those with microscopy-positive p. Falciparum parasitemia are treated at baseline. Parasitemia, hemoglobin, plasma cytokines, plasma metabolites, and inflammatory markers will be measured at baseline and at follow-up. Successful completion of this project will determine whether treatment of asymptomatic p. Falciparum infections leads to improvements in cognitive performance and whether systemic inflammation mediates this relationship. Understanding these relationships is essential for developing public health programs that reduce the impact of malaria and its sequelae.

Transactions

Action Obligated Date
Amendment -$0
Amendment $115,309
Amendment $115,309
Amendment $29,539
Amendment $29,539
Amendment $265,851
Amendment $265,851
Original award $265,851

Subawards

Subrecipient Amount Awarded
Centre For Global Health And Child Development Kenya The work to be covered will include, but not be limited to: provision of necessary study personnel and direct management of subcontracted study funds;… $7,149
Centre For Global Health And Child Development Kenya $80,640

Quick answers

Who received award R21AI180840?

R21AI180840 was awarded to Trustees Of Indiana University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on January 25, 2024.

How much is award R21AI180840 worth?

$1,087,249 has been obligated on R21AI180840.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award